Corestemchemon Inc

166480

Company Profile

  • Business description

    Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.

  • Contact

    Pangyo 255 beongil 24 I & C Building, 2nd Floor
    yeonggi-do, Bundang-gu
    Seongnam
    Seoul13486
    KOR

    T: +82 24973711

    http://www.corestemchemon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    376

Stocks News & Analysis

stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,015.4048.700.54%
CAC 407,861.964.600.06%
DAX 4024,262.2244.850.19%
Dow JONES (US)44,636.183.190.01%
FTSE 1009,136.940.620.01%
HKSE25,176.93347.52-1.36%
NASDAQ21,185.8787.570.42%
Nikkei 22540,654.7019.85-0.05%
NZX 50 Index12,855.9780.44-0.62%
S&P 5006,382.8812.020.19%
S&P/ASX 2008,756.4051.800.60%
SSE Composite Index3,615.726.010.17%

Market Movers